{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T23:06:55Z","timestamp":1783984015429,"version":"3.55.0"},"reference-count":27,"publisher":"Georg Thieme Verlag KG","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Fortschr Neurol Psychiatr"],"abstract":"ZUSAMMENFASSUNG<\/jats:title>\n Serum-Neurofilament-Leichtkette (sNfL) ist ein Biomarker f\u00fcr neuroaxonalen\n Schaden und korreliert mit klinischer und bildgebender Krankheitsaktivit\u00e4t,\n Hirnatrophie und Behinderungsprogression, ist jedoch nicht krankheitsspezifisch.\n Diese \u00dcbersichtsarbeit fasst aktuelle Aspekte der Messmethodik, Pr\u00e4analytik und\n Interpretation von sNfL zusammen. Besondere Bedeutung haben zentrale\n Einflussfaktoren wie Alter, Body-Mass-Index beziehungsweise Verteilungsvolumen,\n Nierenfunktion sowie andere Einflussfraktoren. F\u00fcr die klinische Anwendung ist\n daher eine standardisierte Bewertung anhand alters- und BMI-korrigierter\n Referenzdaten, etwa \u00fcber Z-Scores oder Perzentile, entscheidend.<\/jats:p>\n Klinisch kann sNfL die initiale Risikostratifizierung und Therapieplanung\n unterst\u00fctzen, im Verlauf als Fr\u00fchwarnsignal f\u00fcr subklinische Krankheitsaktivit\u00e4t\n dienen, die Abgrenzung von Schub und Pseudoschub erleichtern, progrediente\n Verl\u00e4ufe erg\u00e4nzend charakterisieren und Entscheidungen in besonderen Situationen\n wie Schwangerschaft, h\u00f6herem Lebensalter oder Deeskalation begleiten. Dabei sind\n serielle Messungen einzelnen Bestimmungen \u00fcberlegen. Zuk\u00fcnftige Priorit\u00e4ten\n sollten in der Harmonisierung der Assays sowie in prospektiven Studien zu\n NfL-gest\u00fctzten, multimodalen Entscheidungsstrategien liegen.<\/jats:p>","DOI":"10.1055\/a-2873-1243","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T22:54:26Z","timestamp":1783983266000},"source":"Crossref","is-referenced-by-count":0,"title":["Neurofilament-Leichtkette (sNfL) als Instrument zur Beurteilung der\n Krankheitsaktivit\u00e4t und des Therapieansprechens bei Multipler Sklerose\n (MS)"],"prefix":"10.1055","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1377-836X","authenticated-orcid":false,"given":"Hernan","family":"Inojosa","sequence":"additional","affiliation":[{"name":"Medizinische Fakult\u00e4t und Universit\u00e4tsklinikum Carl Gustav Carus,\n Technische Universit\u00e4t Dresden, SN, Germany","place":["Dresden"],"department":["Zentrum f\u00fcr klinische Neurowissenschaften, Klinik und Poliklinik f\u00fcr\n Neurologie"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Akg\u00fcn","sequence":"additional","affiliation":[{"name":"Medizinische Fakult\u00e4t und Universit\u00e4tsklinikum Carl Gustav Carus,\n Technische Universit\u00e4t Dresden, SN, Germany","place":["Dresden"],"department":["Zentrum f\u00fcr klinische Neurowissenschaften, Klinik und Poliklinik f\u00fcr\n Neurologie"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Masanneck","sequence":"additional","affiliation":[{"name":"Medizinische Fakult\u00e4t und Universit\u00e4tsklinikum D\u00fcsseldorf,\n Heinrich-Heine-Universit\u00e4t D\u00fcsseldorf, Germany","place":["D\u00fcsseldorf"],"department":["Klinik f\u00fcr Neurologie"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven G\u00fcnther","family":"Meuth","sequence":"additional","affiliation":[{"name":"Medizinische Fakult\u00e4t und Universit\u00e4tsklinikum D\u00fcsseldorf,\n Heinrich-Heine-Universit\u00e4t D\u00fcsseldorf, Germany","place":["D\u00fcsseldorf"],"department":["Klinik f\u00fcr Neurologie"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Kuhle","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsspital Basel, BS, Switzerland","place":["Basel"],"department":["MS-Zentrum und Forschungszentrum f\u00fcr Klinische Neuroimmunologie und\n Neurowissenschaften Basel (RC2NB), Neurologie"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Bittner","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsmedizin der Johannes Gutenberg-Universit\u00e4t\n Mainz, RP, Germany","place":["Mainz"],"department":["Klinik und Poliklinik f\u00fcr Neurologie"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Khalil","sequence":"additional","affiliation":[{"name":"Medizinische Universit\u00e4t Graz, Styria, Austria","place":["Graz"],"department":["Universit\u00e4tsklinik f\u00fcr Neurologie"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Pawlitzki","sequence":"additional","affiliation":[{"name":"Medizinische Fakult\u00e4t und Universit\u00e4tsklinikum D\u00fcsseldorf,\n Heinrich-Heine-Universit\u00e4t D\u00fcsseldorf, Germany","place":["D\u00fcsseldorf"],"department":["Klinik f\u00fcr Neurologie"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8799-8202","authenticated-orcid":false,"given":"Tjalf","family":"Ziemssen","sequence":"additional","affiliation":[{"name":"Medizinische Fakult\u00e4t und Universit\u00e4tsklinikum Carl Gustav Carus,\n Technische Universit\u00e4t Dresden, SN, Germany","place":["Dresden"],"department":["Zentrum f\u00fcr klinische Neurowissenschaften, Klinik und Poliklinik f\u00fcr\n Neurologie"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2026,7,13]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1001\/jama.2020.26858","article-title":"Diagnosis and Treatment of Multiple Sclerosis: A Review","volume":"325","author":"M P McGinley","year":"2021","journal-title":"Jama."},{"key":"ref2","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41582-018-0058-z","article-title":"Neurofilaments as biomarkers in neurological disorders","volume":"14","author":"M Khalil","year":"2018","journal-title":"Nature reviews Neurology"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1001\/jamaneurol.2019.1534","article-title":"Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in\n Neurology: A Systematic Review and Meta-analysis","volume":"76","author":"C Bridel","year":"2019","journal-title":"JAMA Neurol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ebiom.2015.11.036","article-title":"Plasma Concentration of the Neurofilament Light Protein (NFL) is a Biomarker of\n CNS Injury in HIV Infection: A Cross-Sectional Study","volume":"3","author":"M Gissl\u00e9n","year":"2016","journal-title":"EBioMedicine."},{"key":"ref5","doi-asserted-by":"crossref","first-page":"986","DOI":"10.2337\/dc23-2208","article-title":"Longitudinal Change in Serum Neurofilament Light Chain in Type 2 Diabetes and\n Early Diabetic Polyneuropathy: ADDITION-Denmark","volume":"47","author":"L L M\u00e4\u00e4tt\u00e4","year":"2024","journal-title":"Diabetes Care"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"120447","DOI":"10.1016\/j.cca.2025.120447","article-title":"Validation and generation of age-specific reference intervals for a new blood\n neurofilament light chain assay","volume":"577","author":"R A Booth","year":"2025","journal-title":"Clin Chim Acta"},{"key":"ref7","first-page":"20","article-title":"Advancing Clinical Use of Neurofilament Light Chain: Translational Insights From\n Research to Routine Practice","author":"E La Civita","year":"2025","journal-title":"Biomark Insights"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S1474-4422(22)00009-6","article-title":"Serum neurofilament light chain for individual prognostication of disease\n activity in people with multiple sclerosis: a retrospective modelling and\n validation study","volume":"21","author":"P Benkert","year":"2022","journal-title":"The Lancet Neurology"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1515\/cclm-2025-1476","article-title":"Comparative analysis of three platforms for serum NfL quantification in healthy\n controls and MS patients","volume":"64","author":"J Dargvainiene","year":"2026","journal-title":"Clin Chem Lab Med"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1177\/1352458515623365","article-title":"Serum neurofilament light chain in early relapsing remitting MS is increased and\n correlates with CSF levels and with MRI measures of disease severity","volume":"22","author":"J Kuhle","year":"2016","journal-title":"Multiple sclerosis (Houndmills, Basingstoke, England)"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/ana.24954","article-title":"Serum Neurofilament light: A biomarker of neuronal damage in multiple\n sclerosis","volume":"81","author":"G Disanto","year":"2017","journal-title":"Annals of neurology"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1001\/jamaneurol.2019.3238","article-title":"Serum Neurofilament Light Chain Levels in Patients With Presymptomatic Multiple\n Sclerosis","volume":"77","author":"K Bjornevik","year":"2020","journal-title":"JAMA Neurol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"10381","DOI":"10.1038\/s41598-020-67504-6","article-title":"Serum neurofilament light chain predicts long term clinical outcomes in multiple\n sclerosis","volume":"10","author":"S Thebault","year":"2020","journal-title":"Scientific reports"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/joim.13286","article-title":"Neurofilament light chain as a marker for cortical atrophy in multiple sclerosis\n without radiological signs of disease activity","volume":"290","author":"B V Ineichen","year":"2021","journal-title":"J Intern Med"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1093\/brain\/awy154","article-title":"Serum neurofilament as a predictor of disease worsening and brain and spinal\n cord atrophy in multiple sclerosis","volume":"141","author":"C Barro","year":"2018","journal-title":"Brain : a journal of neurology"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1111\/ene.15742","article-title":"High serum neurofilament light chain levels correlate with brain atrophy and\n physical disability in multiple sclerosis","volume":"30","author":"A Buchmann","year":"2023","journal-title":"European journal of neurology"},{"key":"ref18","first-page":"1324","article-title":"Dimethyl fumarate decreases neurofilament light chain in CSF and blood of\n treatment na\u00efve relapsing MS patients","volume":"90","author":"T Sejbaek","year":"2019","journal-title":"Journal of neurology, neurosurgery, and psychiatry"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1177\/13524585221108080","article-title":"No increase of serum neurofilament light in relapsing-remitting multiple\n sclerosis patients switching from standard to extended-interval dosing of\n natalizumab","volume":"28","author":"M Johnsson","year":"2022","journal-title":"Multiple sclerosis (Houndmills, Basingstoke, England)"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"e1007","DOI":"10.1212\/WNL.0000000000007032","article-title":"Blood neurofilament light chain as a biomarker of MS disease activity and\n treatment response","volume":"92","author":"J Kuhle","year":"2019","journal-title":"Neurology."},{"key":"ref21","doi-asserted-by":"crossref","first-page":"104662","DOI":"10.1016\/j.ebiom.2023.104662","article-title":"Blood neurofilament light levels predict non-relapsing progression following\n anti-CD20 therapy in relapsing and primary progressive multiple sclerosis:\n findings from the ocrelizumab randomised, double-blind phase 3 clinical\n trials","volume":"93","author":"A Bar-Or","year":"2023","journal-title":"EBioMedicine."},{"key":"ref22","doi-asserted-by":"crossref","first-page":"e555","DOI":"10.1212\/NXI.0000000000000555","article-title":"Profiling individual clinical responses by high-frequency serum neurofilament\n assessment in MS","volume":"6","author":"K Akgun","year":"2019","journal-title":"Neurology(R) neuroimmunology & neuroinflammation"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"102463","DOI":"10.1016\/j.msard.2020.102463","article-title":"NFL and CXCL13 may reveal disease activity in clinically and radiologically\n stable MS","volume":"46","author":"L Novakova","year":"2020","journal-title":"Multiple sclerosis and related disorders"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1111\/ene.13965","article-title":"Neurofilament light chain levels in pregnant multiple sclerosis patients: a\n prospective cohort study","volume":"26","author":"J P Cuello","year":"2019","journal-title":"European journal of neurology"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/S1474-4422(23)00154-0","article-title":"Risk of new disease activity in patients with multiple sclerosis who continue or\n discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised,\n single-blind, phase 4, non-inferiority trial","volume":"22","author":"J R Corboy","year":"2023","journal-title":"The Lancet Neurology"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"3851","DOI":"10.1007\/s00415-023-11676-4","article-title":"A multimodal marker for cognitive functioning in multiple sclerosis: the role of\n NfL, GFAP and conventional MRI in predicting cognitive functioning in a\n prospective clinical cohort","volume":"270","author":"M van Dam","year":"2023","journal-title":"Journal of neurology"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1001\/jamaneurol.2022.5250","article-title":"Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as\n a Biomarker for Disease Progression in Multiple Sclerosis","volume":"80","author":"S Meier","year":"2023","journal-title":"JAMA Neurol"},{"key":"ref31","first-page":"16","article-title":"Osteopontin as a diagnostic and NTZ-response biomarker of multiple sclerosis: a\n systematic review and meta-analysis","author":"A Gonz\u00e1lez-Jim\u00e9nez","year":"2025","journal-title":"Frontiers in immunology"}],"container-title":["Fortschritte der Neurologie \u00b7 Psychiatrie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2873-1243.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T22:54:30Z","timestamp":1783983270000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2873-1243"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,13]]},"references-count":27,"URL":"https:\/\/doi.org\/10.1055\/a-2873-1243","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0720-4299","1439-3522"],"issn-type":[{"value":"0720-4299","type":"print"},{"value":"1439-3522","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,13]]}}}